Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Romidepsin

FDA-approved product (powder, intravenous), marketed as Istodax, Romidepsin.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Romidepsin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous T-cell lymphoma
  • Mature T-cell and NK-cell non-Hodgkin lymphoma
  • Neoplasm
  • T-cell non-Hodgkin lymphoma
  • Unspecified peripheral T-cell lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Histone deacetylase (hdac) inhibitors
FDA pharmacologic class
Histone Deacetylase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Romidepsin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-3.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-2.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-3.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Romidepsin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

    NCT01755975 · start 2012-12

    Registered record
    Registry ID
    NCT01755975
    Conditions
    Multiple Myeloma; Non-Hodgkin's Lymphoma
    Interventions
    Romidepsin; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2023-10
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Non-Hodgkin's Lymphoma
    InterventionRomidepsin; Lenalidomide
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

    NCT01590732 · start 2012-10-29

    Registered record
    Registry ID
    NCT01590732
    Conditions
    Mycosis Fungoides; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Hepatosplenic T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
    Interventions
    Carboplatin; Etoposide; Ifosfamide; Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10-29
    Completion
    2018-05-02
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycosis Fungoides; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma +7 more
    InterventionCarboplatin; Etoposide; Ifosfamide; Romidepsin
    PhasePhase 1
    Registry statusCompleted

  • A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma

    NCT01537744 · start 2012-02

    Registered record
    Registry ID
    NCT01537744
    Conditions
    Solid Tumors; Virally Mediated Cancers and Liposarcoma
    Interventions
    oral 5-azacitidine in combination with romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2016-09
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors; Virally Mediated Cancers and Liposarcoma
    Interventionoral 5-azacitidine in combination with romidepsin
    PhasePhase 1
    Registry statusCompleted

  • Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

    NCT01324310 · start 2011-04-01

    Registered record
    Registry ID
    NCT01324310
    Conditions
    Hematologic Malignancy; Malignant Lymphoma
    Interventions
    Romidepsin; Ketoconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04-01
    Completion
    2012-01-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancy; Malignant Lymphoma
    InterventionRomidepsin; Ketoconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas

    NCT01280526 · start 2011-01

    Registered record
    Registry ID
    NCT01280526
    Conditions
    Peripheral T Cell Lymphoma
    Interventions
    Romidepsin and CHOP; Romidepsin and CHOP; Romidepsin and CHOP; Romidepsin and CHOP
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-01
    Completion
    2014-03
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T Cell Lymphoma
    InterventionRomidepsin and CHOP; Romidepsin and CHOP; Romidepsin and CHOP; Romidepsin and CHOP
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma

    NCT01445340 · start 2007-04-21

    Registered record
    Registry ID
    NCT01445340
    Conditions
    Mycosis Fungoides; Cutaneous T-Cell Lymphoma; Neoplasms
    Interventions
    Romidepsin (FR901228)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-04-21
    Completion
    2012-06-29
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycosis Fungoides; Cutaneous T-Cell Lymphoma; Neoplasms
    InterventionRomidepsin (FR901228)
    PhasePhase 1
    Registry statusTerminated

  • A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

    NCT00431990 · start 2006-11

    Registered record
    Registry ID
    NCT00431990
    Conditions
    Multiple Myeloma
    Interventions
    depsipeptide; bortezomib; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2006-11
    Completion
    2012-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    Interventiondepsipeptide; bortezomib; dexamethasone
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    NCT00084682 · start 2005-06

    Registered record
    Registry ID
    NCT00084682
    Conditions
    Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx
    Interventions
    romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-06
    Completion
    2012-03
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx
    Interventionromidepsin
    PhasePhase 2
    Registry statusCompleted

  • FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

    NCT00085527 · start 2005-05

    Registered record
    Registry ID
    NCT00085527
    Conditions
    Ovarian Cancer
    Interventions
    depsipeptide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2005-05
    Completion
    2005-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    Interventiondepsipeptide
    PhasePhase 2
    Registry statusWithdrawn

  • FR901228 in Treating Patients With Metastatic Breast Cancer

    NCT00098397 · start 2005-02

    Registered record
    Registry ID
    NCT00098397
    Conditions
    Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventions
    romidepsin; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-02
    Completion
    Not recorded
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventionromidepsin; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

    NCT00112463 · start 2005-01-07

    Registered record
    Registry ID
    NCT00112463
    Conditions
    Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Gastrointestinal Stromal Tumor; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    Interventions
    romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-01-07
    Completion
    2008-10-23
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma +16 more
    Interventionromidepsin
    PhasePhase 2
    Registry statusCompleted

  • FR901228 in Treating Patients With Recurrent High-Grade Gliomas

    NCT00085540 · start 2005-01

    Registered record
    Registry ID
    NCT00085540
    Conditions
    Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventions
    depsipeptide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2005-01
    Completion
    2009-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma +1 more
    Interventiondepsipeptide
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

    NCT00094978 · start 2004-10-25

    Registered record
    Registry ID
    NCT00094978
    Conditions
    Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Mesothelioma
    Interventions
    Depsipeptide; Flavopiridol (alvocidib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2004-10-25
    Completion
    2013-05-20
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Mesothelioma
    InterventionDepsipeptide; Flavopiridol (alvocidib)
    PhasePhase 1
    Registry statusTerminated

  • A Research Study for Patients With Prostate Cancer

    NCT00106418 · start 2003-05-07

    Registered record
    Registry ID
    NCT00106418
    Conditions
    Prostate Cancer; Metastases
    Interventions
    Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-05-07
    Completion
    2006-09-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Metastases
    InterventionRomidepsin
    PhasePhase 2
    Registry statusCompleted

  • Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    NCT00062075 · start 2003-05

    Registered record
    Registry ID
    NCT00062075
    Conditions
    Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13; q22); Adult Acute Myeloid Leukemia With t(15; 17)(q22; q12); Adult Acute Myeloid Leukemia With t(16; 16)(p13; q22); Adult Acute Myeloid Leukemia With t(8; 21)(q22; q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia
    Interventions
    romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-05
    Completion
    Not recorded
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13; q22) +11 more
    Interventionromidepsin
    PhasePhase 2
    Registry statusCompleted